

June 8, 2020



# Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series

**Live video moderated discussion with Dr. Terrence Norchi, CEO, on Monday, June 15, at 12:00 PM ET, immediately followed by an interactive Q&A session**

FRAMINGHAM, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the [Virtual Investor Fireside Chat Series](#) on Monday, June 15, 2020 at 12:00 PM ET. The conference is being held on June 15-17, 2020.

Dr. Norchi and Mr. Richard Davis, Chief Financial Officer, will participate in an interactive Q&A session with listeners immediately following the fireside chat, and they will be available for 1x1 virtual meetings during the conference. Investors who are registered to attend the event may request a one-on-one meeting with management through the conference website ([vifiresidechat.com](http://vifiresidechat.com)) or by email ([info@virtualinvestorco.com](mailto:info@virtualinvestorco.com)).

To access the live [video webcast](#) of the fireside chat, please visit: [https://event.webcasts.com/starthere.jsp?ei=1329095&tp\\_key=5ded2be477](https://event.webcasts.com/starthere.jsp?ei=1329095&tp_key=5ded2be477).

A replay of the webcast will be available two hours later: <https://ir.archtherapeutics.com/ir-calendar>.

For more information about the event, please visit: [vifiresidechat.com](http://vifiresidechat.com).

## **About Arch Therapeutics, Inc.**

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5 Advanced Wound System, AC5 Topical Hemostat, AC5-G and AC5 Surgical Hemostat.<sup>1, 2</sup>

## **Notice Regarding Forward-Looking Statements**

This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include,

among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at [www.sec.gov](http://www.sec.gov).

## Contact

ARTH Investor Relations

Toll Free: +1-855-340-ARTH (2784) (US and Canada)

Email: [investors@archtherapeutics.com](mailto:investors@archtherapeutics.com)

Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)

or

Richard Davis

Chief Financial Officer

Arch Therapeutics, Inc.

Phone: 617-431-2308

Email: [rdavis@archtherapeutics.com](mailto:rdavis@archtherapeutics.com)

Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)

1. AC5 Surgical Hemostat is currently an investigational device limited by law to investigational use.
2. AC5 and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.



Source: Arch Therapeutics, Inc.